Arkolith/Insider Trading/INBX/Form 4

Eckelman Brendan P.

Chief Scientific OfficerInhibrx, Inc. (INBX) · full profile →Form 4 · filed May 30, 2024
Net Selling
Open-Market Buys
$0
Open-Market Sells
$10.3M
Net Open-Market Flow
-$10.3M
Transactions
6
4 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 30, 2024Disposed to issuer(D)160K$30.00$4.8M0
May 30, 2024Disposed to issuer(D)160K$30.00$4.8M0
May 30, 2024Disposed to issuer(D)1.7M$30.00$52.1M0
May 28, 2024Sell(S)300K$34.30$10.3M1.7M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 30, 2024Disposed to issuer(D)7K——0
May 30, 2024Disposed to issuer(D)27K——0

Transaction Codes

D
Disposition to the issuer
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950142-24-001497) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML